
XTNT Stock Forecast & Price Target
XTNT Analyst Ratings
Bulls say
Xtant Medical Holdings is a medical technology company with a focus on developing and commercializing spinal implant systems and orthobiologics. The company has a strong portfolio of products used by orthopedic surgeons to treat various spinal disorders, and has recently increased its revenue guidance for FY26 thanks to a new agreement with Dilon Technologies. Despite past struggles with achieving scale and attention from investors, XTNT's current efforts to grow into a $150M-$200M global orthobiologics company present a favorable risk/reward opportunity. With a strong capital position and increasing interest from distributors, we anticipate faster-than-expected top-line growth, particularly in the orthobiologics segment, leading to potential share price appreciation.
Bears say
Xtant Medical Holdings is a medical technology company focused on orthobiologic and spinal implant systems for spinal fusion procedures. The company has recently launched a new addition to its bone graft portfolio and raised its revenue guidance for FY26, which could lead to increased revenue and improved gross margins. However, the company still faces risks from competition, legacy performance, and the need for additional capital. The company trades at a discount to its peers and is expected to continue growing through the launch of new products and increasing distributor interest.
This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.
XTNT Analyst Forecast & Price Prediction
Start investing in XTNT
Order type
Buy in
Order amount
Est. shares
0 shares